Absorption of testosterone gel 1% (Testim) from three different application sites

Journal of Sexual Medicine

Volumn 6, Issue 9, 2009, Pages 2601-2610

  Guay, Andre T ^a   Smith, Ted M ^b   Offutt, Laura A ^b  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b Auxilium Pharmaceuticals   (United States)

Author keywords

Aging men; Hypogonadism; Testosterone; Testosterone deficiency Syndrome; Topical treatment

Indexed keywords

ALBUMIN; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; ANDROGEN; GEL;

ABDOMEN; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG FORMULATION; DRUG SAFETY; GEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGONADISM; LEG; MALE; MORNING DOSAGE; NORMAL VALUE; PRIORITY JOURNAL; SHOULDER; SKIN IRRITATION; TESTOSTERONE BLOOD LEVEL; THORAX; ADMINISTRATION AND DOSAGE; AGE; AGING; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; MIDDLE AGED; PROSPECTIVE STUDY; THERAPEUTIC USE;

AGE FACTORS; AGING; ANALYSIS OF VARIANCE; ANDROGENS; GELS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TESTOSTERONE;

EID: 69949083527     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01366.x     Document Type: Article

References (43)

1. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920-6.
2. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: The HIM Study. Int J Clin Pract 2006;60:762-9.
3. Bouloux P. Testim 1% testosterone gel for the treatment of male hypogonadism. Clin Ther 2005;27:286-98.
4. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31.
5. Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of Testim® 1% testosterone gel in hypogonadal men. Rev Urol 2005;7:87-94.
6. Maggi M, Schulman C, Quinton R, Langham S, Uhl-Hochgraeber K. The burden of testosterone deficiency syndrome in adult men: Economic and quality-of-life impact. J Sex Med 2007;4:1056-69.
7. Ellegala DB, Alden TD, Couture DE, Vance ML, Maartens NF, Laws ER Jr. Anemia, testosterone, and pituitary adenoma in men. J Neurosurg 2003;98:974-7.
8. Kohler TS, Kim J, Feia K, Bodie J, Johnson N, Makhlouf A, Monga M. Prevalence of androgen deficiency in men with erectile dysfunction. Urology 2008;71:693-7.
9. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010.
10. Freeman ER, Bloom DA, McGuire EJ. A brief history of testosterone. J Urol 2001;165:371-3.
11. Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ. Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 1988;11:247-64.
12. Auxilium Pharmaceuticals I. TESTIM ® 1% (testosterone gel) [Prescribing information]. Malvern, PA: Auxilium Pharmaceuticals, Inc. ; 2006, February.
13. Solvay Pharmaceuticals I. AndroGel ® (testosterone gel) 1 % [Prescribing Information]. Marietta, GA: Solvay Pharmaceuticals; 2007.
14. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM III. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239-42.
15. Sodergard R, Backström T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-10.
16. ISSA. MFree and bioavailable testosterone calculator. Available at: http://www.issam.ch/freetesto.htm (accessed July 21, 2008).
17. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FCW. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur Urol 2009;55:121-30.
18. Corona G, Mannucci E, Ricca V, Lotti F, Boddi V, Bandini E, Balercia G, Forti G, Maggi M. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 2009 Feb 10. [Epub ahead of print]doi:10.1111/ j.1365-2605.2009.00952x.
19. Guay A, Jacobson J. The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med 2007;4:1046-55.
20. Wespes E, Schulman CC. Male andropause: Myth, reality, and treatment. Int J Impot Res 2002;14(suppl 1):S93-8.
21. Hong BS, Ahn TY. Recent trends in the treatment of testosterone deficiency syndrome. Int J Urol 2007;14:981-5.
22. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Andol 1994;15:212-5.
23. Fabbri A, Giannetta E, Lenzi A, Isidori AM. Testosterone treatment to mimic hormone physiology in androgen replacement therapy. A view on testosterone gel and other preparations available. Expert Opin Biol Ther 2007;7:1093-106.
24. Edelstein D, Sivanandy M, Shahani S, Basaria S. The latest options and future agents for treating male hypogonadism. Expert Opin Pharmacother 2007;8:2991-3008.
25. McGriff NJ, Csako G, Kabbani M, Diep L, Chrousos GP, Pucino F. Treatment options for a patient experiencing pruritic rash associated with transdermal testosterone: A review of the literature. Pharmacotherapy 2001;21:1425-35.
26. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007;4:497-501.
27. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 1982;37:425-30.
28. Chiang HS, Cho SL, Lin YC, Hwang TI. Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: Evaluation by IIEF score. Urology 2009;73:762-6.
29. Marbury T, Hamill E, Bachand R, Sebree T, Smith T. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim TM, compared to AndroGel®. Biopharm Drug Dispos 2003;24:115-20.
30. Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res 2008;20:213-7.
31. Bain J. The many faces of testosterone. Clin Interv Aging 2007;2:567-76.
32. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-98.
33. Brand TC, Canby-Hagino E, Thompson IM. Testosterone replacement therapy and prostate cancer: A word of caution. Curr Urol Rep 2007;8:185-9.
34. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85:2670-7.
35. Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82:1661-7.
36. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839-53.
37. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469-78.
38. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom, BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-72.
39. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis. J Clin Endocrinol Metab 1997;82:3793-6.
40. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001;56:M266-72.
41. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: A quantitative review of prospective studies. Br J Cancer 1999;80:930-4.
42. Gooren LJ, Bunck MC. Androgen replacement therapy: Present and future. Drugs 2004;64:1861-91.
43. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol 2005;63:280-93.